| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/18/2008 | US20080311102 Nucleic acid molecule that encodes the MGAT-X1 protein; pharmaceutical composition containing the nucleic acid or its expression vector |
| 12/18/2008 | US20080311101 Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals |
| 12/18/2008 | US20080311100 Treatment of Keratinous Dryness With Glycerides |
| 12/18/2008 | US20080311098 Compounds and methods for modulating the immune response against antigens |
| 12/18/2008 | US20080311089 Augmentation and Repair of Vocal Cord Tissue Defects |
| 12/18/2008 | US20080311083 Methods of Modulating Beta Cell Function |
| 12/18/2008 | US20080311079 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 12/18/2008 | US20080311078 Self-Buffering Protein Formulations |
| 12/18/2008 | US20080311077 Antiviral Compounds |
| 12/18/2008 | US20080311076 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents |
| 12/18/2008 | US20080311075 Hepatitis C Virus Inhibitors |
| 12/18/2008 | US20080311074 Inhibitors against activation of NF-kappaB |
| 12/18/2008 | US20080311056 treating and preventing tooth decay; remove selectively cariogenic bacteria or to decrease the number of cariogenic bacteria inside oral cavity, and may exert preventive effect against tooth caries |
| 12/18/2008 | US20080311051 Caspase-2 Inhibitors And Their Biological Applications |
| 12/18/2008 | US20080311043 Uses and compositions for treatment of psoriatic arthritis |
| 12/18/2008 | US20080311042 Loop-Variant Pdz Domains as Biotherapeutics, Diagnostics and Research Reagents |
| 12/18/2008 | US20080311040 METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| 12/18/2008 | DE60224400T2 Hepatitis c virus polymerase inhibitoren mit heterobicylischer struktur Hepatitis C virus polymerase inhibitors with heterobicylischer structure |
| 12/18/2008 | CA2692854A1 Ace2 polypeptide |
| 12/18/2008 | CA2692019A1 Cell-proliferation inhibiting vpg proteins, fragments or analogs thereof and their applications |
| 12/18/2008 | CA2690905A1 Recombinant transferrin mutants |
| 12/18/2008 | CA2690715A1 Peptide slow-release formulations |
| 12/18/2008 | CA2690345A1 .beta.gbp, compositions comprising .beta.gbp, and related methods and uses thereof |
| 12/18/2008 | CA2690267A1 Small cationic antimicrobial peptides |
| 12/18/2008 | CA2690218A1 Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| 12/18/2008 | CA2689602A1 Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
| 12/18/2008 | CA2689549A1 Igf for the treatment of rett syndrome and synaptic disorders |
| 12/18/2008 | CA2689492A1 Natriuretic fusion proteins |
| 12/18/2008 | CA2688265A1 Selective cell therapy for the treatment of renal failure |
| 12/18/2008 | CA2688256A1 Methods of modulating inflammation and compositions therefore |
| 12/18/2008 | CA2687896A1 Inhibitors of receptor tyrosine kinases and methods of use thereof |
| 12/18/2008 | CA2687746A1 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 12/18/2008 | CA2687614A1 Methods for preparing diazonamides |
| 12/18/2008 | CA2687123A1 Method for the treatment of atopic eczema |
| 12/18/2008 | CA2684780A1 Formation of proteoliposomes containing membrane proteins by means of an acellular protein synthesis system |
| 12/17/2008 | EP2003207A2 Antisense inhibition of PTP1B expression |
| 12/17/2008 | EP2003203A1 Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily |
| 12/17/2008 | EP2003202A2 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 12/17/2008 | EP2003201A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 12/17/2008 | EP2003198A2 Peptide for inhibition of influenza infection, inhibitor of influenza infection, liposome, and prophylactic/therapeutic agent for influenza |
| 12/17/2008 | EP2003197A2 Synergistic effect between a cyanogenic system and another oxidative inducer for the treatment of tumours |
| 12/17/2008 | EP2003143A1 Cell-proliferation inhibiting VPg proteins, fragments or analogs thereof and their applications |
| 12/17/2008 | EP2003142A1 Amorphous perindopril erbumine |
| 12/17/2008 | EP2002846A2 Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
| 12/17/2008 | EP2002842A2 Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator |
| 12/17/2008 | EP2002827A2 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 12/17/2008 | EP2002263A2 Cancer immunotherapy compositions and methods of use |
| 12/17/2008 | EP2002036A2 Compositions and methods related to profiling a plurality of cell lines based on peptide binding |
| 12/17/2008 | EP2002005A1 Identification of crmp4 as a convergent regulator of axon outgrowth inhibition |
| 12/17/2008 | EP2001906A2 Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| 12/17/2008 | EP2001903A2 Long-acting polypeptides and methods of producing and administering same |
| 12/17/2008 | EP2001523A2 Variably crosslinked tissue |
| 12/17/2008 | EP2001518A2 Cyclic natriuretic peptide constructs |
| 12/17/2008 | EP2001512A2 Use of the staudinger ligation in in vivo assembly of a biologically active compound |
| 12/17/2008 | EP2001509A1 Pharmaceuticals for influencing the reaction of the human immune system |
| 12/17/2008 | EP2001507A2 Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/diagnostic use |
| 12/17/2008 | EP2001505A2 Cathepsin propeptide and uses thereof |
| 12/17/2008 | EP2001504A2 Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| 12/17/2008 | EP2001503A2 Diagnosis and treatment of alzheimer's disease |
| 12/17/2008 | EP2001502A1 Parenteral low dose type 1 interferons for bladder cancer |
| 12/17/2008 | EP2001501A2 Method to reduce the risk and/or severity of anthrax infection |
| 12/17/2008 | EP2001500A2 Formulations for ecallantide |
| 12/17/2008 | EP2001499A2 Use of tsg-6 for treating bone diseases |
| 12/17/2008 | EP2001497A2 Pharmaceutical compositions |
| 12/17/2008 | EP2001495A2 Methods for regulating neurotransmitter systems by inducing counteradaptations |
| 12/17/2008 | EP2001490A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 12/17/2008 | EP2001455A2 Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| 12/17/2008 | EP2001453A2 Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia |
| 12/17/2008 | EP2001452A2 Calcium phosphate complex in acid containing chewing gum |
| 12/17/2008 | EP2001400A2 Oral formulations of glycyl-2-methylprolyl-glutamate |
| 12/17/2008 | EP2001350A2 Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same |
| 12/17/2008 | EP1843791A4 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis |
| 12/17/2008 | EP1641434B1 Pharmaceutical formulations for intranasal administration of protein comprising chitosan or a derivative thereof |
| 12/17/2008 | EP1639903B1 Composition and foods for lowering glycemic index |
| 12/17/2008 | EP1572889B1 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| 12/17/2008 | EP1536778B1 Proteins binding to cross-beta structure comprising amyloid and methods for modulation of the cross-beta structure, its formation and its associated toxicity |
| 12/17/2008 | EP1530592B1 Chimeric mhc protein and oligomer thereof |
| 12/17/2008 | EP1274449B1 Methods for manipulating upper gastrointestinal transit, blood flow, for inducing satiety |
| 12/17/2008 | EP1230214B1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 12/17/2008 | EP1024829B1 Tolerogenic fragments of natural allergens |
| 12/17/2008 | EP1007696B1 Il-13 receptor specific chimeric proteins and uses thereof |
| 12/17/2008 | EP1007673B1 Novel bone mineralization proteins, dna, vectors, expression systems |
| 12/17/2008 | EP0966297B1 Regulation of gastrointestinal motility |
| 12/17/2008 | EP0910342B1 Temperature sensitive gel for sustained delivery of protein drugs |
| 12/17/2008 | EP0909317B1 Compositions for modulating the length of telomeres |
| 12/17/2008 | EP0791067B1 Protein kinase npk-110 |
| 12/17/2008 | CN101325969A Method of using IL6 antagonists with proteasome inhibitors |
| 12/17/2008 | CN101325965A Use of transferrins for treating destructive inflammation of mucous membrane |
| 12/17/2008 | CN101325964A Vip片段和应用方法 Vip fragments and application methods |
| 12/17/2008 | CN101325963A Compstatin and analogs thereof for eye disorders |
| 12/17/2008 | CN101325951A Leucine rich composition |
| 12/17/2008 | CN101325944A Compositions for nasal delivery |
| 12/17/2008 | CN101323860A Novel biological method for detoxification |
| 12/17/2008 | CN101323643A Optimized TACI-Fc fuse protein |
| 12/17/2008 | CN101323641A Anti-opioid peptide, antagonistic peptide thereof and use thereof |
| 12/17/2008 | CN101323640A Enzymolysis product inhibiting alpha-glucosidase activity and use thereof |
| 12/17/2008 | CN101322840A Human cystathionine beta-synthetase recombinant protein and use |
| 12/17/2008 | CN101322839A Formulation for increasing calcium absorption |
| 12/17/2008 | CN101322838A Formulation for replenishing calcium |
| 12/17/2008 | CN101322837A Formulation for increasing bone density |